No headlines found.
No press releases found.
No news found.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
Advanced Biomed trades on the NASDAQ stock market under the symbol ADVB.
As of August 26, 2026, ADVB stock price climbed to $9.24 with 569,920 million shares trading.
ADVB has a beta of 0.73, meaning it tends to be less sensitive to market movements. ADVB has a correlation of 0.00 to the broad based SPY ETF.
ADVB has a market cap of $15.10 million. This is considered a Sub-Micro Cap stock.
ADVB has underperformed the market in the last year with a return of +4.3%, while SPY returned +19.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ADVB shares. However, ADVB has outperformed the market in the last 3 month and 2 week periods, returning +132.2% and +21.6%, while SPY returned +2.3% and -0.8%, respectively. This indicates ADVB has been having a stronger performance recently.
ADVB support price is $8.11 and resistance is $10.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADVB shares will trade within this expected range on the day.
